F. Cibien

Genetic subclonal complexity and miR125a-5p down-regulatio identify a subset of patients with inferior outcome in low-ris CLL patients

M. Ferracin, M. Negrini, A. Cuneo, 2013, Oncotarget.

Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real‐life campus CLL study

R. Foà, S. Molica, A. Cuneo, 2021, American journal of hematology.

Clonal evolution including 14q32/IGH translocations in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients

A. Cuneo, L. Rizzotto, S. Martinelli, 2012, Leukemia & lymphoma.

Diagnostic work-up for clinical and prognostic assessment of acute leukaemia

M. Negrini, A. Cuneo, S. Moretti, 2012, La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine.

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients

R. Fanin, F. Gherlinzoni, G. Pizzolo, 2018, Oncotarget.

Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group

R. Foà, M. Vignetti, G. Gaidano, 2020, Hematological oncology.

Molecular cytogenetic lesions in chronic lymphocytic leukemia

A. Cuneo, G. Rigolin, F. Cavazzini, 2009 .

Circulating endothelial cells in patients with chronic lymphocytic leukemia

A. Cuneo, R. Marasca, L. Rizzotto, 2010, Cancer.

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study

R. Foà, S. Molica, A. Cuneo, 2022, Frontiers in Oncology.

Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters.

M. Negrini, R. Fanin, P. Galieni, 2012, Blood.